Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Monopar Therapeutics Inc ( (MNPR) ) has issued an announcement.
On April 19, 2026, Monopar Therapeutics reported new analyses from the randomized Phase 3 FoCus trial showing that ALXN1840 (tiomolibdate choline) delivered greater neurologic benefit than standard of care in Wilson disease patients with neurologic symptoms at baseline. Presented at the American Academy of Neurology 2026 meeting, the Week 48 data indicated higher rates of neurologic improvement, lower rates of neurologic worsening, and superior CGI-S and CGI-I scores versus existing therapies.
Longer-term follow-up showed that neurologic benefits in ALXN1840-treated patients continued to increase and were sustained for roughly three years, with consistent efficacy in both treatment-naïve and treatment-experienced subgroups. Across Phase 2 and 3 studies totaling 266 patients and 645 patient-years of exposure, ALXN1840 also exhibited a favorable safety profile, with low rates of drug-related serious adverse events and no treatment-related deaths, reinforcing its potential to reshape neurologic management in Wilson disease.
These results underscore ALXN1840’s role as a potential first-in-class Albumin Tripartite Complex activator that improves copper balance by enhancing fecal copper excretion and limiting copper-driven neurologic damage. The strength and durability of the efficacy and safety data position ALXN1840 as a key late-stage asset for Monopar and could significantly enhance the company’s standing in the rare disease space if the program advances successfully through regulatory review.
The most recent analyst rating on (MNPR) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on Monopar Therapeutics Inc stock, see the MNPR Stock Forecast page.
Spark’s Take on MNPR Stock
According to Spark, TipRanks’ AI Analyst, MNPR is a Neutral.
The score is primarily held back by weak financial performance (pre-revenue profile, persistent losses, and ongoing cash burn) and bearish technical trend signals (trading below key moving averages with negative MACD). A positive offset is the commercialization-oriented executive hire, while valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on MNPR stock, click here.
More about Monopar Therapeutics Inc
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs. Its pipeline includes late-stage ALXN1840 for Wilson disease and several MNPR-101-based radiopharmaceutical programs in early clinical and preclinical development for imaging and treating advanced cancers.
The company targets rare disease and oncology markets, aiming to advance both small-molecule and radiopharmaceutical candidates. Monopar is listed on Nasdaq under the ticker MNPR and is working to progress its lead assets through late-stage development toward potential regulatory submissions and commercialization.
Average Trading Volume: 225,449
Technical Sentiment Signal: Hold
Current Market Cap: $387.5M
For a thorough assessment of MNPR stock, go to TipRanks’ Stock Analysis page.